一个新的治疗组合显示,在广泛阶段的小细胞肺癌方面,结果非常明显,71%的病人作出反应,产生可管理的副作用。 A new treatment combo showed strong results in extensive-stage small cell lung cancer, with 71% of patients responding and manageable side effects.

第1b阶段试验发现,在一线化疗和PD-L1抑制剂维持疗法中增加沥青(Imdelltra)会导致71%的客观反应率和11个月的中位反应期,在大片小细胞肺癌患者中,39%至少保持了1年的疾病控制。 A phase 1b trial found that adding tarlatamab (Imdelltra) to first-line chemotherapy and PD-L1 inhibitor maintenance therapy led to a 71% objective response rate and a median response duration of 11 months in extensive-stage small cell lung cancer patients, with 39% maintaining disease control for at least a year. 疗程显示一种可管理的安全情况,大多数副作用是可以管理的,没有意外毒性。 The regimen showed a manageable safety profile, with most side effects being manageable, and no unexpected toxicity. 结果在2025年ESMO大会上发表,并发表在"柳叶刀瘤学"杂志上. Results were presented at the 2025 ESMO Congress and published in The Lancet Oncology.